District of Columbiamed spa & injectable regulations
What’s changing for med spas and injectors in District of Columbia — GLP-1 compounding, scope-of-practice, and enforcement — plus the federal FDA and Federal Register actions that apply in District of Columbia. Med Spa Radar monitors it all and tells you, in plain language, what changed and what to do.
Latest District of Columbia changes
No District of Columbia-specific changes have crossed our radar yet — we’re actively monitoring the District of Columbia legislature and licensing boards. The federal changes below apply to every District of Columbia practice today.
Federal changes that apply in District of Columbia
FDA and Federal Register actions are nationwide — they govern District of Columbia practices too.
- CRITICALFEDERALFDA Enforcement2025-09-10
FDA recall (Class II): Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy
FDA recalls compounded GLP-1 product for being subpotent.
- CRITICALFEDERALFDA Enforcement2025-08-13
FDA recall (Class II): Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Steri…
FDA recalls compounded GLP-1 product; check your stock now!
- CRITICALFEDERALFDA Enforcement2026-01-07
FDA recall (Class II): Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880…
FDA recalls Wegovy; med spas must check supplies!
- CRITICALFEDERALFDA Enforcement2026-03-11
FDA recall (Class II): Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061,…
FDA recalls Semaglutide for sterility issues—act now!
- CRITICALFEDERALFDA Enforcement2026-01-07
FDA recall (Class II): Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 B…
FDA recalls Wegovy due to safety concerns; med spas must act.
- CRITICALFEDERALFDA Enforcement2025-07-02
FDA recall (Class II): Semaglutide, 2.5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80…
FDA recalls GLP-1 product over sterility issues.
What we monitor in District of Columbia
- District of Columbia legislature — bills on injectables, GLP-1s & scope of practice
- District of Columbia Board of Nursing — injector scope & delegation
- District of Columbia Medical Board — physician supervision & ownership rules
- District of Columbia Board of Pharmacy — compounding & 503A/503B
- U.S. FDA — enforcement, warning letters, recalls, shortages
- Federal Register — new rules on compounding & aesthetics
District of Columbia med spa compliance — FAQ
- Where do District of Columbia med spa and injectable regulations come from?
- District of Columbia med spas and injectors are governed by a mix of state and federal authorities — the District of Columbia legislature, and the state's boards of nursing, medicine, and pharmacy, alongside federal bodies like the FDA and the Federal Register. Med Spa Radar monitors all of them for District of Columbia and flags what changed in plain language.
- Does the FDA's GLP-1 compounding guidance apply in District of Columbia?
- Yes — federal FDA actions on GLP-1 compounding (semaglutide, tirzepatide) apply nationwide, including in District of Columbia. We track those federal changes alongside any District of Columbia-specific rules so you see the full picture for your practice.
- How do I keep up with District of Columbia regulatory changes?
- Med Spa Radar sends a free weekly Brief on what changed across District of Columbia, the FDA, and the Federal Register. Members get the exact "what to do" for their states in real time. It's regulatory monitoring, not legal advice.
Never miss a District of Columbia change
Get the free weekly Brief on what changed across District of Columbia, the FDA, and the Federal Register. Members get the exact what-to-do, in real time, for their states.
Get the free Brief →← All states · Regulatory monitoring, not legal advice.